President's Report 2009

A lb an y Colleg e of Pharmacy and Health S cien c es

Wh y What We Do

Matters to You

2009 P r es i d e n t ’s R e po r t

editor

Donna Reichel

contributing writers

Gil Chorbajian / James J. Gozzo, Ph.D. President / Patrick Rathbun / Donna Reichel

contributing photographers design

Coppola Design

Eric Atkinson / Mark McCarty / Kris Qua

Improving the quality of life for kidney disease patients. Making drugs safer.

Assessing and managing diabetes.

Protecting the skin from sun damage.

Developing nanopharmaceuticals for cancer patients. Optimizing drug dosing and treatment strategies.

Because what we do, matters to you.

ACPHS President’s Report 2009

Pr esid ent’s M essag e

>

5

Faculty

>

6

Students

> 2 2

Alumni

> 2 6

F inancial Repo r t

> 2 8

Sch olar ly Repo r t

> 3 0

>

ACPHS President’s Report 2009

President’s Message

Welcome to the annual review of research and scholarly activity at Albany College of Pharmacy and Health Sciences.

As you will read in the following pages, faculty, staff, students and alumni of the College are today studying several of our most complex and pervasive disease states, such as obesity, cancer, kidney disease, diabetes and bladder dysfunction.

The significance of the work that we are doing has taken on added importance over the past year. At the time of this writing, health care reform is still being debated in Congress and at the heart of the discussions are the issues of quality, accessibility and affordability. The research projects profiled here have the potential to cut across each of these areas.

As we continue our commitment to the expansion of knowledge of human health, we recognize that many of today’s research breakthroughs are defined by collaborations, and the College is actively engaged in developing such relationships. Dr. Mousa, whose international collaborations were profiled in last year’s Report, is working with researchers at RPI and the University of North Carolina on the formulation of a biosynthetic equivalent to the popular blood thinner Heparin that will be safer than the current version of the drug.

There are also a number of collaborations occurring within the walls of the College. Over the past several years, ACPHS has also developed concentrations of faculty with specialties in nephrology, infectious disease and health outcomes assessment. The members of these teams offer a powerful combination of knowledge and expertise that allows the College to pursue a more expansive range of research projects.

The College’s ability to further impact the future of health care was enhanced by two important developments this year — the fall 2009 opening of our Vermont satellite campus and the introduction of a Master’s Degree in Pharmaceutical Sciences. Dr. Balaz, Chair of the Department of Pharmaceutical Sciences at the Vermont campus, received a $1.35 million NIH grant to develop a computer modeling approach that will simulate how new and experimental drugs will react in the body, which may help researchers reduce the time and costs associated with bringing new drugs to the market. Master’s student Alaa Hammad is also making an important contribution, assisting Dr. Hass in her investigations of new ways to protect the skin from the harmful rays of the sun.

At ACPHS, our mission is the advancement of health, and research is one of the keys to achieving this objective. By studying the practice, delivery and costs of health care, the research we do here holds the promise of one day impacting how we manage some of our greatest health threats.

It’s why what we do, matters to you.

James J. Gozzo, Ph.D. president

5

>

ACPHS President’s Report 2009

Nephrology Faculty Strive to Halt Progress of Kidney Disease

As the largest pharmacy faculty group specializing in the study of the kidneys, the Albany Nephrology Pharmacy Group at ACPHS operates like a think tank. The five faculty who comprise the group investigate various areas of kidney disease and treatment options with one goal in mind: to raise awareness of what they see as an epidemic and find the best diagnostic and treatment options for the 1 in 9 adults who have the disease.

Members of the group, which also goes by the name ANephRx, work both individually and collectively to bring new treatment options to those suffering with this disease. The group includes: Magdalene Assimon, Nephrology Pharmacy Fellow; George Bailie, Pharm.D., Ph.D., FCCP, FASN; Katie Cardone, Pharm.D.; Darren Grabe, Pharm.D.; Darius Mason, Pharm.D., BCPS; and Amy Barton Pai, Pharm.D., BCPS, FASN.

With few warning signs, most kidney disease is found during routine clinical visits. According to Bailie, “The disease has the same mortality rate as colon cancer and yet most people don’t get screened when they should. They can have it for years before it’s detected during a routine checkup. Unfortunately, a great deal of the time, the disease has progressed to where the patient needs dialysis.”

This group is passionate about the work that they do. They not only focus on research, they reach out to the community via programs such as free kidney screenings held on the campus. Cardone says, “We work closely with the National Kidney Foundation to offer screenings on campus. Early detection is the key. You can’t cure the disease, but you can stop it from progressing.”

The College was recently recognized by the National Kidney Foundation of Northeast New York with its “Contributions to Health Care Award,” due to the efforts of the ANephRx

team. In presenting the award, the NKF stated, “Your work in the renal field has been instrumental in the treatment of patients with chronic kidney disease. The expertise your faculty lends at the local and national level has helped us to educate thousands of health care professionals throughout the country.”

One area of focus for the group is the study of IV iron. Most patients who have kidney disease are anemic and regulating the amount of iron they have becomes problematic.

According to Grabe, “We are studying what the most effective dosage would be with the least amount of side effects. We focus on tissue models, animals and humans. These studies are reviewed worldwide and will eventually impact patient care.”

Another area of study is Vitamin D and understanding its relationship to bone disease and heart problems. “As anemia worsens, it not only affects your bones, but it affects your heart as well. We are trying to find the most effective level of Vitamin D to treat this loss and ward off heart disease,” says Bailie.

Collaboration is important not only within the group but with other researchers on campus as well. They have worked with the ACPHS infectious disease group to determine the optimal dosing of several antibiotics in patients on dialysis. Cardone states, “Since the kidneys are necessary to remove medications from the body, patients with little or no kidney function are not able to eliminate antibiotics.

Both groups have collaborated to determine the optimal dosing of several antibiotics in patients on dialysis.”

Bailie says that their research is making a difference in the lives of patients with kidney disease. “Our findings help clinicians treat patients with the correct medication at the proper levels with the least amount of side effects,” he says. “We want to improve the quality of life for each individual suffering from this disease.”

7

>

ACPHS President’s Report 2009

9

Infectious Disease Group Studying Disease Treatment Strategies

priate timing and dosing for antibiotic regimens.

The faculty members focus their efforts on four key populations: elderly, obese, HIV-infected and kidney-diseased patients.

With strong expertise in research and patient care, five faculty members in the Department of Pharmacy Practice have formed an Infectious Disease group.

The group aims to better understand a variety of infectious diseases and improve clinical practice in the treatment of these conditions. Specific objectives include developing antibiotic regimens that improve patient outcomes, reduce toxicity and minimize antibiotic resistance.

The members of the group, who include Thomas Lodise, Pharm.D., Amit Pai, Pharm.D., Christopher Miller, Pharm.D., Tony Nicasio, Pharm.D., and Nimish Patel, Pharm.D., focus on epidemiology and the outcomes of infections.

To make their findings transferable to patient care, the group uses mathematical modeling to help identify the proper antibiotics, in addition to determining the appro-

“With the global emergence of multi-drug resistant bacteria in hospital institutions, clinicians are currently presented with an extreme challenge when selecting an appropriate antibiotic treatment option,” Nicasio said. “This dilemma has created a real need for more sophisticated research into this subject matter.”

The aforementioned populations comprise a large and emerging segment of the global population.

For example, one in three Americans are obese, almost 40 million Americans are older than 65, one million Americans will require dialysis by the year 2015, and more than 33 million people worldwide live with HIV. The health care costs associated with obesity are estimated to be $150 billion per year. HIV drugs can cost thousands of dollars per month for individual patients.

“Optimizing drug dosing and treatment strategies in special populations will

roviral therapy. Nicasio researches treatments for hospital-bound patients with strong bacterial infections. improve health outcomes and reduce overall health care costs,” Lodise said.

“We strive to play a part through the design of improved antimicrobial dosing regimens and treatment strategies.”

For his efforts in infectious disease, Lodise received four grants last year to study the “super bacteria” methicillin-resistant staphylococcus aureus (MRSA) and the antibiotics used to treat infections associated with it. Patel will work with Lodise on MRSA until his postdoctoral fellowship ends in July. Patel will then join the ACPHS faculty to focus on HIV and Hepatitis C exposure and response research.

Pai received a grant last year from Pfizer to study the pharmacokinetics of Voriconazole in obese subjects (Voriconazole is a drug used to treat fungal infections in patients with compromised immune systems). Miller studies drug interactions in subjects engaged in antiret-

In addition to these areas of research, Infectious Disease group members make frequent regional and national presentations to educate the health care community about their findings. The group also provides pharmacotherapy and clinical research training to pharmacy students.

Soon, the group plans to create opportunities for interested ACPHS students to pursue a concentration in infectious diseases pharmacotherapy and research, thereby demonstrating the College’s continuing commitment to this important work.

>

ACPHS President’s Report 2009

Stefan Balaz, Ph.D. Chair and Professor of Pharmaceutical Sciences Vermont Campus

w h at h e ’ s w o r k ing o n >

Balaz has been awarded a five year grant from the National Institutes of Health (NIH) in the amount of $1,350,000. Balaz and his team are developing an approach that will allow researchers to simulate the rate at which drugs are

transported through the membranes of the body.

The results of their work will be incorporated into software that will help predict the effectiveness and safety of drugs under development.

W h y i t ’ s imp o r ta n t t o y o u >

Allowing researchers to better model how new and experimental drugs will act in the body will speed the time-to-market for these drugs and reduce the costs associated with research and development. The net result is decreased waiting time for the approval of new drugs and lower costs for patients purchasing these medications.

11

>

ACPHS President’s Report 2009

Shaker A. Mousa, Ph.D. Executive Vice President and Chairman Pharmaceutical Research Institute (PRI) Professor of Pharmaceutical Sciences W h at h e ’ s w o r k ing o n >

Mousa is part of a team of researchers that has been awarded a $4.7 million grant from the National Institutes of Health to develop a biosynthetic equivalent of the drug Heparin.

Heparin, a very popular blood thinner used in hospitals throughout the world, is extracted from swine intestines and, as such, the potential exists for contamination.

Mousa is working with researchers from Rensselaer Polytechnic Institute (RPI) and the University of North Carolina (UNC) on the project. The grant will take place over the next five years and the goals are to produce a non-animal derived and controlled version of the drug, ensure that it is as effective as today’s Heparin and demonstrate that it can be produced at a scale and cost needed to satisfy demand.

Why it’s imp o r ta n t t o y o u >

According to the FDA, the contaminant in Heparin is known to cause allergic reactions and hypotension (low blood pressure) in some patients, with adverse reactions severe enough to cause death in some cases. In 2008 more than 100 people in the U.S. alone died after being administered contaminated doses of Heparin and some estimate that figure to be even higher.

A biosynthetic version of the drug would represent a safer alternative for patients and eliminate the possibility of deaths related to contamination.

13

>

ACPHS President’s Report 2009

Margaret Malone, Ph.D. R.Ph. FCCP Professor of Pharmacy Practice

W h at s h e ’ s w o r k ing o n >

Malone received a grant in the amount of $25,000 from GlaxoSmithKline Consumer Health Care to study Alli®, the over the counter weight loss drug, in the Management of Pre-Operative Weight Loss. Bariatric surgery is a procedure performed on people who have clinically severe obesity, usually meaning they are at least

100 pounds overweight.

Weight loss of approximately 10% prior to this surgery is required to help decrease operative time and reduce the surgical risks. This study will evaluate the benefit of using Alli® with clinical support to help patients achieve a 10% weight loss prior to bariatric surgery.

Why it’s imp o r ta n t t o y o u >

The number of patients undergoing weight loss surgery is increasing rapidly nationwide.

If Alli® is shown to be effective in this setting it could be a helpful aid since many insurers provide limited or no coverage for any currently available weight loss medications, which may be prescribed for patients considering weight loss surgery.

It would also provide a lower cost, readily available alternative that, along with diet and exercise programs, would help people qualify for bariatric surgery, a critical step towards living healthier lives.

15

>

ACPHS President’s Report 2009

Michael P. Kane, Pharm.D.,FCCP,BCPS Professor of Pharmacy Practice

W h at h e ’ s w o r k ing o n >

Kane received a $49,000 grant from Abbott Diabetes Care to study the accuracy of various glucose meters.

Blood glucose test strips and meters are used by diabetes patients to monitor their blood glucose levels. Both brand name and lower cost generic blood glucose meters and test strips are available to patients, but to date, no direct comparison of the accuracy of these meters has been published.

Why it’s imp o r ta n t t o y o u >

Good glucose control in diabetes patients helps prevent and control diabetes related complications such as blindness, kidney disease and nerve damage. Glucose meters and test strips that are inexpensive, easy to use, and accurate would give more patients the ability to assess and manage their diabetes and decrease the risks of long term diabetes related complications.

17

>

ACPHS President’s Report 2009

Robert M. Levin, Ph.D. Professor of Pharmaceutical Sciences

W h at h e ’ s w o r k ing o n >

Levin received a grant in the amount of $83,000 from Astellas Pharma Global Development to study new therapies in the treatment of lower urinary tract dysfunctions (LUTD). The incidences of LUTD in both men and women increase with age.

Symptoms can be debilitating and include urgency, increased frequency, frequent need to urinate at night and painful urination.

In women, incontinence is a major problem and in men the inability to urinate exists. The major goals of Levin’s research grant are to identify the processes that cause age-related LUTD in both men and women and develop novel and effective therapies for these patients. One therapy in particular which shows promise involves the use of antioxidants.

Why it’s imp o r ta n t t o y o u >

Taking antioxidants such as coenzyme Q10*, alpha lipoic acid**, vitamin C, and vitamin E beginning early in adult life may be effective in reducing the rate of age-related LUTD, resulting in improved health, fewer doctor visits and cost savings due to the avoidance of expensive prescription medications. This study aims to identify the antioxidants that will have the greatest impact in slowing or eliminating incidences of LUTD.

* Found in fresh fish such as sardines and mackerel as well as beef, lamb, pork, eggs, spinach and broccoli. For optimum results, food should be fresh, raw and unprocessed. ** Found in dark green leafy vegetables, spinach, collard greens, broccoli as well as organ meats and beef steak.

19

>

ACPHS President’s Report 2009

21

Amit Pai, Pharm.D. Associate Professor of Pharmacy Practice

W h at h e ’ s w o r k ing o n >

Pai has been awarded two Investigator Initiated Clinical Grants. One from Pfizer Inc. in the amount of $109,397 and another from Roche Laboratories Inc. in the amount of $237,530.

Dr. Pai and his co-investigators will be studying the protocols used to administer antimicrobials to obese patients suffering from infections.

The dosage of drugs is typically studied in normal weight healthy volunteers.

As a result, the dosing guidelines determined in these studies may be too low and fail if given as a fixed dose to obese patients. Alternatively, the dose may be too high and toxic if prescribed based on total body weight.

W h y i t ’ s imp o r ta n t t o y o u >

The right dosage for the right weight.

Improving the antimicrobial dosing guidelines for obese patients with infections would shorten the treatment periods, produce improved outcomes and potentially save lives.

>

ACPHS President’s Report 2009

23

Vijay Venugopal ’10 Student in the Bachelor’s Program in Pharmaceutical Sciences

M o s t R e c e n t P r o j e c t at AC P H S >

Venugopal worked with Robert Levin, Ph.D., to study the effects of grapes on the rabbit urinary bladder.

Their research explored additional therapy for those afflicted with benign prostatic hyperplasia, or BPH. Previous studies using a rabbit model of BPH clearly demonstrated that feeding rabbits grapes protected the bladder from damage caused by the release of free radicals.

Alaa Hammad Student in the Master’s Program in Pharmaceutical Sciences

W h at s h e ’ s w o r k ing o n >

W h y i t ’ s imp o r ta n t t o y o u >

The ultraviolet radiation in natural sunlight can damage the skin in a variety of ways, including sunburn, photoaging and skin cancer. Hammad is assisting Martha Hass Ph.D., Associate Professor in Arts and Sciences, in testing a series of new drugs for use as topical agents that will help protect the skin from sun damage by replenishing the natural antioxidants that are depleted by solar radiation.

Most sunblocks have only one active ingredient that is absorbed into the skin, but the topical agents that Hammad is working on will use compounds derived from both vitamin E and lipoic acid. Once activated these ingredients will work cooperatively to provide an enhanced level of protection when compared to most of the products now on the market.

W h y i t ’ s I mp o r ta n t t o Y o u >

The particular study that Venugopal worked on demonstrated that one of the mechanisms by which grapes protect the bladder is by direct protection of mitochondria, which are in every cell and supply energy for all cellular functions.

Just a handful of grapes everyday can make a difference!

Daily consumption of grapes allows for saturation of high enough levels of antioxidants in the bladder tissue to prevent damage caused by ischemia (low blood flow) and free radicals. The benefits include maintaining and/or improving the integrity of one’s bladder function, as well as promoting good tissue health and function.

>

ACPHS President’s Report 2009

Alexandra Rehfuss ’09 First Year Student at Albany Medical College

Under the mentorship of Robert Levin, Ph.D., professor in the Department of Pharmaceutical Sciences at ACPHS, Rehfuss studied bladder dysfunction in women. Her research included studying the effects of cycling estrogen on the female bladder and the correlation to interstitial cystitis, an often debilitating disease that results in pain in the bladder and pelvic region. Interstitial cystitis is most commonly found in women after puberty, but then goes into remission after menopause.

Their research showed there is a direct connection between cycling estrogen levels and this disease.

W h y i t ’ s imp o r ta n t t o y o u >

This research will help physicians further understand interstitial cystitis and potentially aid in the formulation of more effective treatment plans for patients who suffer from the disease.

25

>

ACPHS President’s Report 2009

27

David P. DeMagistris, Ph.D. ’77 Senior Vice President, Pharmaceutical Sciences and Manufacturing Cerulean Pharma Inc. Cambridge, MA W h at h e ’ s w o r k ing o n >

DeMagistris works in the emerging field of nanopharmaceuticals, where he helps develop nanotechnology based drug delivery systems at Cerulean.

Nanopharmaceuticals use ultra-small particles measured in nanometers (a nanometer is one billionth of a meter) to target the root causes of disease.

These drug containing particles are designed

W h y i t ’ s imp o r ta n t t o y o u >

to enhance treatment medications by delivering drugs to specific diseased tissues, controlling the release of therapeutic concentrations of drugs over a short or prolonged period of time, and improving formulations of established therapies. Cerulean has two nanotechnology platforms, one currently in clinical trials for oncology.

Nanopharmaceuticals have many applications, but one area of that offers great promise is in the treatment of cancer, which remains an area of high unmet medical need.

Nanotechnology-based therapeutics have the

potential to be more effective and better tolerated by cancer patients than traditional treatments, resulting in improved outcomes and extended patient life without the harmful side effects often associated with cancer therapies.

Susan M. Learned, Pharm.D., Ph.D. ’91 Head of Discovery Medicine, North America Neurosciences Center of Excellence for Drug Discovery GlaxoSmithKline

W h at s h e ’ s w o r k ing o n >

As a clinical pharmacologist, Learned leads a group of physicians and scientists that are responsible for studying every new neurology and psychiatry drug developed by GlaxoSmithKline. Through early clinical studies, her group works to identify the correct dosage of a new drug, ensuring its safety and tolerability. Once the

W h y i t ’ s imp o r ta n t t o y o u >

safety and tolerability have been characterized, they design trials to test the efficacy of the drug for the target disease. A key objective of her group is to determine early in clinical development whether a compound is likely to be better than medicines already available on the market, helping to ensure that compounds that do

not have the proper profile are not progressed, while those that show significant promise receive the proper resources to enable further development. Her current areas of research include: depression, anxiety disorders, dementia and cognition, schizophrenia, Bipolar Disorder, sleep disorders, pain and addiction.

By the time a drug is available to the public, it has been tested in humans so that the product you take is effective, safe and at the correct dosage. The medicines that Learned’s group helps to develop address the significant need for better treatments of neurological and psychiatric diseases.

>

ACPHS President’s Report 2009

Balance Sheet

As of June 30, 2009 3.2%

A SSET S

Cash and Cash Equivalents $ 10,258,998 Investments 17,834,285 Other Assets 2,097,698 Accounts Receivable-Students 665,575 Receivables-Government Entities 1,658,679 Other Receivables 707,883 Pledges Receivable 1,489,790 Student Loans Receivable 2,409,495 Agency Funds 230,276 Deposits with bond Trustess 1,326,662 Property, Plant & Equipment-Net 48,699,171 Total Assets $ 87,378,512

Other Sources

2.53%

Gifts and Pledges

Revenues

0.44% Postgraduate Education 6.85%

Government Contracts and Grants

77.68%

Student Tuition and Fees

Investment Income 0.47%

8.83%

Auxiliary Enterprises

L I A B I LIT I E S A N D N ET A SS ETS

Liabilities Line of credit $ 0 Accounts payable and accrued liabilities 1,461,955 Deferred income and deposits 8,557,604 U.S. government grants refundable 2,167,797 Bonds Payable 29,423,224 Capital lease obligation 0 Expected Post Retirement Benefit Obligation 981,145 Other liabilities 578,506 Deposits held in custody for others 230,276 Total Liabilities $ 43,400,507 Net Assets UNRESTRICTED: For current operations $ 9,255,317 Funds functioning as an endowment 4,063,095 Designated for plant capital 2,126,611 Plant Fund 22,692,841 Total Unrestricted Net Assets $ 38,137,864 TEMPORARILY RESTRICTED: Unexpended funds received for restricted purposes Total Temporarily Restricted Net Assets

$ $

8.24% Physical Plant

25.16%

0.33% Postgraduate Education

Instruction/Student Services

39.93% 16.46%

Student Financial Aid

General Administration

1.68%

Expenses

1,180,862 1,180,862

PERMANENTLY RESTRICTED: Endowment Funds $ 4,624,929 O’Brien Loan Fund 34,350 Total permanently restricted net assets 4,659,279 Total Net Assets 43,978,005 Total Liabilities and Net Assets $ 87,378,512

Research

3.47%

Investment Losses

4.73%

Institutional Advancement

29

>

ACPHS President’s Report 2009

Pharmaceutical Research Institute

Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine. 2008 Dec;4(4):273-82.

P u b l i c at io n s

Bharali DJ, Pradhan V, Elkin G, Qi W, Hutson A, Mousa SA, Thanavala Y. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine.

Nanomedicine. 2008 Dec;4(4):311-7.

Shaker Mousa Norey E, Simone TM, Mousa SA. The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand. Appl Health Econ Health Policy. 2008;6(2-3):93-102.

Mousa SA, Bergh JJ, Dier E, Rebbaa A, O’Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis. 2008;11(2):183-90.

Norey E, Simone TM, Mousa SA. The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand. Appl Health Econ Health Policy. 2008; 6(2-3):93-102.

Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis.

2008;11(3):269-76.

Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther.

2008;324(3):894-901.

Ovsag K, Hydery S, Mousa SA: Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag. 2008;4(2):403-13.

Fares RR, Lansing LS, Gallati CA, Mousa SA. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opin Pharmacother. 2008;9(3):377-86.

Aljada A, O’Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis. 2008;11(4):361-7.

Chu F, Chou P, Mirkin BL, Mousa SA, Rebbaa A. Cellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway. Aging Cell. 2008 Aug;7(4):516-25.

Park TJ, Lee SH, Simmons TJ, Martin JG, Mousa SA, Snezhkova EA, Sarnatskaya VV, Nikolaev VG, Linhardt RJ. Heparin-cellulosecharcoal composites for drug detoxification prepared using room temperature ionic liquids.

Chem Commun. 2008 Oct 28;(40):5022-4.

Zheng X, Chu F, Mirkin BL, Sudha T, Mousa SA, Rebbaa A. Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta.

2008 Dec;1783(12):2294-300.

Mousa SA. Novel Anticoagulant Therapy: Principle and Practice. Thrombin: Physiology and Disease. 2009:237-257.

Mousa SA. Emerging Links Between Thrombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low-Molecular-Weight Heparins. New Therapeutic Agents in Thrombosis and Thromobolysis. 2009:289-305.

care unit: a prospective observational study.

Cardiovasc Ther. 2009;27(2):77-82.

Aljada A, Shah KA, Mousa SA. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res. 2009:460-764.

Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA, Rebbaa A. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol. 2009 Jan;296(1):65-74.

Al-Bloushi S, Safer AM, Afzal M, Mousa SA. Green tea modulates reserpine toxicity in animal models. J Toxicol Sci. 2009 Feb;34(1):77-87.

Kemp MM, Kumar A, Mousa S, Park TJ, Ajayan P, Kubotera N, Mousa SA, Linhardt RJ. Synthesis of Gold and Silver Nanoparticles Stabilized with Glycosaminoglycans Having Distinctive Biological Activities. Biomacromolecules. 2009 Feb 18.

Mousa SA. Overview of Antiplatelet Therapy.

New Therapeutic Agents in Thrombosis and Thromobolysis. 2009:399-408.

Davis PJ, Zhou M, Davis FB, Lansing L, Mousa SA, Lin HY. Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiol Behav.

2009 Feb 25.

Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.

Int J Nanomedicine. 2009;4:1-7.

Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA: Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol.

2009 Mar;88(3):239-43.

Barone C, Mousa SS, Mousa SA. Pharmacoenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine. Pharmacogenomics and Personalized Medicine. 2009;2:1-9.

Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009 Mar 1;69(5):1712-6.

Greene R, Mousa SS, Ardawi M, Qari M, Mousa SA. Pharmacogenomics in osteoporosis: Steps toward personalized medicine. Pharmacogenomics and Personalized Medicine. 2009;2:1-10.

Clarke H, Mousa SA. The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent.

Pharmacogenomics and Personalized Medicine.

2009;2:93-99.

Avery P, Mousa SS, Mousa SA. Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.

Pharmacogenomics and Personalized Medicine.

2009;2:1-13.

Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.

Int J Nanomedicine. 2009;4(1):1-7.

Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol. 2009;41(7):1441-51.

Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary

Park BC, Park SY, Lee JS, Mousa SA, Kim JT, Kwak MK, Kang KW, Lee ES, Choi HG, Yong CS, Kim JA. The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol. 2009 Mar-Apr;50(3-4):123-31.

Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ. L-Thyroxine vs. 3,5,3’-Triiodo-LThyronine and Cell Proliferation: Activation of Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase. Am J Physiol Cell Physiol. 2009 May;296(5):980-91.

Martin JW, Mousa SS, Shaker O, Mousa SA. The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol. 2009 Jun;18(6):497-505.

Kemp MM, Kumar A, Clement D, Ajayan P, Mousa S, Linhardt RJ. Hyaluronan- and heparinreduced silver nanoparticles with antimicrobial properties. Nanomed. 2009 Jun;4(4):421-9.

Lin HY, Davis PJ, Tang HY, Mousa SA, Luidens MK, Hercbergs AH, Davis FB. The pro-apoptotic

action of stilbene-induced COX-2 in cancer cells: Convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle. 2009 Jun 15;8(12):1877-82.

Bridoux A, Cui H, Dyskin E, Yalcin M, Mousa SA. Semisynthesis and pharmacological activities of Tetrac analogs: Angiogenesis modulators.

Bioorg Med Chem Lett. 2009 Jun 15; 19(12):325963.

Larocque J, Bharali DJ, Mousa SA. Cancer Detection and Treatment: The Role of Nanomedicines. Mol Biotechnol. 2009 Jul;42(3):358-66.

Suwan J, Zhang Z, Li B, Vongchan P, Meepowpan P, Zhang F, Mousa SA, Mousa S, Premanode B, Kongtawelert P, Linhardt RJ. Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity. Carbohydr Res. 2009 Jul 6;344(10):1190-6.

Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009 Aug;102(2):258-67.

Mousa SA, Sudha T, Dyskin E, Dier U, Gallati C, Hanko C, Chittur SV, Rebbaa A. Stress resistant human embryonic stem cells as a potential source for the identification of novel cancer stem cell markers. Cancer Lett. 2009 Sep 3.

Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK. Translational Implications of Nongenomic Actions of Thyroid Hormone Initiated at its Integrin Receptor. Am J Physiol Endocrinol Metab. 2009 Sep 15.

G r a n t s a n d Co n t r a c t s Shaker Mousa PROJECT: Development of a Bioengineered Heparin from a Non-Animal Source SPONSOR: Renssalaer Polytechnic Institute (National Institute of Allergies and Infectious Diseases, NIH) TERM: 08/01/09-04/30/2014 TOTAL GRANT: $654,500 PROJECT: Site directed delivery in breast cancer using Novel Angiogenesis Inhibitor SPONSOR: National Cancer Institute (NIH; R21) TERM: 08/07/09-07/31/2011 TOTAL GRANT: $372,680 PROJECT: Studying the Efficacy of Cyt-1010 in Solution and Preparing cyt-1010 nanoparticles SPONSOR: Cytogel, LLC TERM: 02/26/09-until complete TOTAL CONTRACT: $40,000 PROJECT: Steps to Prove the Viability of the BIDS Concept SPONSOR: Avant Garde Therapeutics Technology (AGTT) TERM: 10/23/08-10/22/2010 TOTAL CONTRACT: $729,230

PROJECT: Development and testing of polyvalent anthrax toxin inhibitors SPONSOR: University of Toronto (NIH-NIAID) TERM: 08/01/08-07/31/2013 TOTAL GRANT: $890,503 PROJECT: Compounding Method Development Agreement SPONSOR: US Pharmacopeia TERM: 11/04/08-01/31/2010 TOTAL GRANT: $30,000 PROJECT: Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion SPONSOR: NIH-NCI TERM: 04/04/08-01/31/2010 TOTAL GRANT: $368,445 PROJECT: US/Egypt USAID – Exchange program SPONSOR: NIH TERM: 06/21/07-08/31/2010 TOTAL GRANT: $24,950 PROJECT: Development of Nano Filtration Systems for Removal of Chemotherapeutic Agents SPONSOR: Delcath Systems, Inc. TERM: 12/28/07-11/30/2009 TOTAL CONTRACT: $333,850 PROJECT: Military Medical Research and Development SPONSOR: Department of Defense TERM: 04/01/07-03/09/2010 TOTAL GRANT: $377,620 PROJECT: Testing Novel Modulators of HDL SPONSOR: Vascular Vision Pharmaceuticals TERM: 07/27/09-07/26/2010 TOTAL GRANT: $75,000 A b s t r a c t s / P r e s e n tat io n s The Pharmaceutical Research Institute members presented at several National and International Meetings in 2008-2009.

Pharmacy Practice P u b l i c at io n s Michael Brodeur Brodeur MR. Geriatric Urological Disorders.

In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo, BJ, Alldredge BK, editors. Applied Therapeutics. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2008: 101-1-101-32.

Katie Pallotta Cardone Pallotta KE, Elwell RJ, Nornoo AO, Manley HJ. Stability of tobramycin and ceftazidime in icodextrin peritoneal dialysis solution. Peritoneal Dialysis International. 2009 Jan-Feb;29 (1):52-7.

Jennifer Cerulli Cerulli J, Malone M. Women’s health promotion within a community advanced pharmacy prac-

31

tice experience. American Journal of Pharmacy Education. 2008 Apr 15;72(2):25.

Zeolla MM, Cerulli J. Use of and familiarity with dietary supplement information references by practicing pharmacists. Journal of the American Pharmacist’s Association. 2008 May-Jun;48(3):401-4.

Cerulli J. Documenting Patient Care in the Community Pharmacy Setting. Goode JV, Weitzel K, editors. In: Community Pharmacy Practice Case Studies. Washington DC: American Pharmacists Association; 2009: 17-18.

Jessica Farrell Farrell J, Gumanov D. Propoxyphene: An Antiquated Analgesic. CORRONA News. 2009 Aug;3(2):7-8.

Farrell J. Patient Assistance Programs for Biologics. CORRONA News. 2009 Aug;3(2):9.

Farrell J, Siddon A. Sodium Oxybate (Xyrem) for Fibromyalgia. CORRONA News. 2009 Aug;3(2):10.

Farrell J, Siddon A. Vitamin D Can Help Your Heart, Too? CORRONA News. 2009 Aug;3(2):11-12.

Farrell J. FDA Updates: Rheumatology. CORRONNA News. 2009;3(2):12-14.

Gina Garrison Garrison GD, Lubowski TJ, Miller SM, Strang AF, Sorum PC, Hamilton RA. A Multi-site Pharmacy Student Coronary Heart Disease Risk Assessment Service in the Ambulatory Care Setting: Experiential Education and Patient Satisfaction. American Journal of Pharmacy Education (in press).

Thomas Lodise Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagnostic Microbiology and Infectious Disease. 2008 May;61(1):96-102.

Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrobial Agents and Chemotherapy.

2008 Jul;52(7):2300-4.

Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrobial Agents and Chemotherapy. 2008 Sep;52(9):3315-20.

Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, Stellrecht K. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy. 2008 Nov;62(5):1138-1141.

>

ACPHS President’s Report 2009

Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL. Management of meningitis due to antibiotic-Resistant Acinetobacter species. The Lancet Infectious Diseases. 2009 Apr; 9(4):245-255.

Anne Myrka Gross K, Myrka A. Interdisciplinary learning across the curriculum a description of the use of a “roving professor.” The Chronicle of Higher Education. 2009 Jan;55(20):A34.

Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock. American Journal of Therapeutics.

2009 Jun 13.

Lee Anna Obos Obos LA, Reed M. Pharmaceutical Calculations. In: Durgin, JM ed. Durgin & Hanan’s Pharmacy Practice for Technicians. Delmar Publishers; 2009.

Patel GW, Patel N, Lat A, Trombley KC, Enbawe S, Smith R, Lodise TP. Outcomes of extended infusion piperacillin/tazobactam for documented Gram negative infections. Diagnostic Microbiology and Infect Disease. 2009 Jun;64(2): 236–240.

Amy Barton Pai Boyd A, McQuade CR, Conner TA, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Letter. Hemodial Int. 2009; 89-90.

Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration time profile and nephrotoxicity among hospitalized patients.

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

2009 Aug 15;49(4):507 14.

Nicole Stack Lodise Manley HJ and Stack NM. Smoking cessation therapy considerations for patients with chronic kidney disease. Nephrology Nursing Journal: Journal of the American Nurses’ Association.

2008 Jul-Aug;35(4):357-63,394,quiz 364.

Margaret Malone Malone M. Recommended nutritional supplements for bariatric surgery patients. The Annals of Pharmacotherapy. 2008 Dec;42(12):1851-8.

Malone M. The obesity pandemic: how did we get here? The Annals of Pharmacotherapy. 2009; 98-9.

Cerulli J, Lomaestro BM, Malone M. Update on the Pharmacotherapy of Obesity. The Annals of Pharmacotherapy. 2009; 300-312.

Pai AB, Boyd A, Chavez A, Manley HJ. Healthrelated quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study. Hemodialysis International: International Symposium on Home Hemodialysis. 2009 Jan;13 (1):72-79.

Pai AB, Conner TA, McQuade CR. Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opinion on Drug Metabolism and Toxicology. 2009 Jan;5(1):71-81.

Demirovic J, Pai AB, Pai MP. Estimation of creatining clearance in morbidly obese patients.

American Journal of Health System Pharmacy.

2009 Apr 1;66(7):642-648.

Nimish Patel Patel N, McNutt LA, Lodise TP. Predictors of piperacillin-resistant Pseudomonas aeruginosa among patients with respiratory tract infections: the predictive value of varying exposure definitions and the risk of multiple prior antibiotic exposures. Antimicrobial Agents and Chemotherapy. 2008 Aug;52(8):2933-6.

Patrick Meek Choung RS, Shah ND, Meek PD, Locke R, Talley N. Increasing use of narcotics and functional bowel disorders in the United States. Am J Gastro. 2008;103(S1):S470.

Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-Negative infections. Diagnostic Microbiology and Infectious Disease. 2009 Jun;64(2):236-40.

Perez A, Doloresco F, Hoffman JM, Meek PD, et al. ACCP: economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 2009 Jan;29(1):128.

Sarah Scarpace Scarpace SL. Renal cell carcinoma: review and recent advances. The Oncology Pharmacist/ The Oncology Nurse. 2009;2(3):5-9, 41.

Meek PD, Renaud-Mutart AC, Cosler LE. Electronic medical record use and warfarin drug-drug interactions during ambulatory visits in the United States, 2003-2006. Value Health. 2009 May;12(3):A158.

Scarpace SL, Brodzik FA, Mehdi S, Belgam R. Treatment of head and neck cancers: issues for clinical pharmacists. Pharmacotherapy. 2009 May;29(5):578-92.

Christopher Miller Miller CD, Adams J, Patel N. Next Generation Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Are they an answer to NNRTI resistance? Society of Infectious Diseases Pharmacists Newsletter. 2008 Jun;18(2):14-22.

Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. The Annals of Pharmacotherapy. 2009 Sept;43:1445-55.

Joanna Schwartz McCourt C, Young M, Schwartz J, Young W, DiSilvestro P, Brard L, Tejada-Berges T, Bradley A, Dizon, D. Factors associated with response to taxanes as a later-line treatment of recurrent

ovarian cancer. International Journal of Gynecologic Cancer. 2009 Apr;19(3):343-347.

Schwartz J, Toste B, and Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2m2. Gynecologic Oncology. 2009 Jun;114(3):53-6.

A b s t r a c t s / P r e s e n tat io n s Laurie Briceland Briceland LL. Revised ACPE Standards: Panel Discussion of New York Colleges of Pharmacy.

Presented at the New York State Council of Health-System Pharmacists Midyear Clinical Meeting, Syracuse, NY, October 7, 2008.

Briceland LL. Student Reflective Portfolios.

Presented at Preceptor Training, Albany College of Pharmacy and Health Sciences, Albany, NY, October 14, 2008.

Briceland LL. Preceptor Primer: How to Be a Top-Notch Preceptor. Presented at the Annual Assembly of New York State Council of Health System Pharmacists, Bolton Landing, NY, May 2, 2009.

Briceland LL, Lubowski TL, Scarpace SL. Creation and Implementation of a Public Health Advanced Pharmacy Practice Experience (APPE): Inaugural Year Outcomes. Presented at the AACP 2009 Annual Meeting, Boston, MA, July 18, 2009.

Briceland LL, Denio JJ, Clarke DW. Development and Utilization of Interview/Writing Rubrics to Guide Admissions Decisions into the First Professional Year. Presented at the 2009 American Association of Colleges of Pharmacy Annual Meeting, Boston, MA, July 21, 2009.

Michael Brodeur Brodeur MR. Benign Prostatic Hyperplasia: Update 2008. Presented at the Continuing Education Program, Albany College of Pharmacy and Health Sciences, Albany, NY, September 2008.

Brodeur MR. Geriatric Pharmacotherapy.

Presented at the Metro Health Home Care, Schenectady, NY, September 2008.

Brodeur MR. Which one will it be? Morphine, fentanyl, midazolam & diazepam. Presented at the 5th Annual EMS Symposium, Albany Medical Center Department of Emergency Medicine, January 2009.

Brodeur MR. A Case Study in Chronic Constipation: Diagnosis & Treatment in Long-Term Care Residents. Presented at the CT ASCP Senior Symposium, April 2009.

Brodeur MR, Joffee L. NDMS Pharmacy Operations and Points of Dispensing. Presented at the National Disaster Medical System, Department of Health and Human Services, Westchester Medical Center, June 28, 2009.

Brodeur MR, Cash B. A Case-Based Discussion on Managing Chronic Constipation. Presented at the ASCP Annual Meeting, New Orleans LA, November 2009.

Andy Flynn Flynn A, Ludwick M, Strang A. NYS Board Review. Presented at the PSSNY Midwinter Convention, January 2009.

Katie Pallotta Cardone Cardone KE, Giovinazzo T, Manley HJ, Grabe DW, Meola S, Hoy CD, Bailie GR. Presented at the Medication regimen complexity in patients receiving daily nocturnal home hemodialysis (DNHD). American Society of Nephrology Renal Week 2009, San Diego, CA, October 29, 2009.

Gina Garrison Garrison G, Van der Kloet K. APhA Pharmacybased Immunization Delivery certificate training program. Presented at the Albany College of Pharmacy and Health Sciences, Albany, NY, April 25, 2009.

Jennifer Cerulli Cerulli J. Achieving Performance Improvement in Ongoing Management of Osteoporosis.

Presented at the Tufts Health Plan, Watertown, MA, June 2008.

Cerulli J. Educational Best Practices: Community Pharmacy Practice Experience Target Intervention Programs to Increase Appropriate Use of OTC Calcium and Aspirin. Presented at the American Pharmacists Association Self Care Institute, June 21, 2008.

Cerulli J, Cerulli C, Santos EJ, White AM, Tu X, Johnson K. Does Intimate Partner Violence Victims’ Mental Health Medication Burden Warrant Pharmacies as Portals for Intervention? Presented at the AACP Annual Meeting, July 2008.

Grassi M, Blustein L, Cerulli J, Denio J, Dugan S, Lodise N, Mc Graw P, McArdle R, Policastro C, Schallehn B. Student-Driven Initiative for Substance Abuse Prevention (ISAP). Presented at the AACP Annual Meeting, July 2008.

Cerulli J. Reducing Medication Error: Does Counseling Help? Presented at the PharmEd Continuing Education Conference. Albany, NY, February 25, 2009; Flushing, NY, May 24, 2009.

D’Addario A, Cerulli J, Bryant K, Manella V. Implementing MTM in a Supermarket Pharmacy setting: practical considerations and program outcomes. Presented at the APHA Annual Meeting, April 2009.

Cerulli C, Cerulli J, Santos EJ, White AM, Tu X, Johnson K. Does Intimate Partner Violence Victims’ Mental Health Medication Burden Warrant Pharmacies as Portals for Intervention? Presented at the APHA Annual Meeting, April 2009.

Cerulli J. What Can I Do to Reduce Medication Errors in My Pharmacy? Presented at the Capital Area Pharmacists Association Annual Meeting, Saratoga, NY, April 26, 2009.

Cerulli J. Asthma: Improving Outcomes in Pharmacy Practice. Presented at the PharmEd Continuing Education Conference, Flushing, NY, May 24, 2009.

Sara Dugan Dugan SE. ADHD Update: Medications and Recommended Practice. Presented at the Tinsley Institute, Troy, NY, September 23, 2008.

Garrison G. Cardiovascular Therapeutics Update (Part 1 of 2). Presented at the Board Exam review and CE program, Albany College of Pharmacy and Health Sciences, Albany, NY, May 14, 2009.

Garrison GD, Baia PL. Interactive Teaching Technology in the Large Classroom: Enhancing “Generation M” Student Engagement and Perceptions. Presented at the 2009 American Association of Colleges of Pharmacy Annual Meeting, Boston, MA, July 2009.

Darren Grabe Pallotta KE, Peck B, Manley HJ, Grabe DW. Medication Reconciliation in an Outpatient Hemodialysis Clinic. Presented at the American College of Clinical Pharmacy 2008 Annual Meeting, Louisville, KY, October 2008.

Grabe, DW. Assuring safe and appropriate management of anemia in two patient populations: Cancer and chronic kidney disease. Presented at the ASHP Midyear Clinical Meeting, Orlando, FL, December 9, 2008.

Grabe D. Update on the Management of Chromic Kidney Disease related anemia: Controversies and potential reconciliations.

Presented at the ChemRx Educational Nursing Home Seminar, The Desmond Hotel, Albany, NY, April 22, 2009.

Thomas Lodise Lodise TP. Optimizing Outcomes of Infection.

Presented at the South Carolina College of Pharmacy, Columbia, SC, June 30, 2008; Wayne State University, Detroit, MI, September 6, 2008.

Lodise TP. Applied Antimicrobial Pharmacodynamics: From Bench to Bedside. Presented at the Fletcher Allen Medical Center Hospital Infectious Diseases Grand Rounds, Burlington, VT, September 12, 2008.

Drusano GL, Rodvold KA, Lodise TP, Khashab M, Noel G, Kahn JB, Gottfried M, Nicholson S. Penetration of Ceftobiprole into Epithelial Lining Fluid as Determined by Population Pharmacokinetic Modeling & Calculation of AUC ELF / AUCPlasma Ratio in Healthy Volunteers. Poster presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 2008.

Lodise TP, Patel N, Drusano G. Relationship between Vancomycin Area Under the Concentration-Time Curve (AUC 0-24hr) and Nephrotoxicity.

Presented at the 48th Annual Interscience Conference on Antimicrobial

33

Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington, DC, October 2008.

Drusano GL, Lodise TP, Sorgel F, Mason B, Melnick D. Penetration of Meropenem into Epithelial Lining Fluid of Patients with VentilatorAssociated Pneumonia. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 2008.

Patel GW, Patel N, Lat A, Lodise TP. Outcomes of Extended Infusion Piperacillin/Tazobactam for Documented Gram-Negative Infections. Presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 2008.

Attwood RJ, Davis SL, Lodise TP. Outcomes of P. aeruginosa bacteremia Treated with Piperacillin/tazobactam. Poster presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 2008.

Scheetz MH, Patel N, Drusano GL, Lodise TP. Examination of the Current Renal Dose Adjustment for Piperacillin/Tazobactam. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 2008.

Lodise TP. MRSA: Old Dog with New Tricks.

Presented at the ACPE accredited continuing education, Western Massachusetts Society of Health-System Pharmacists, Springfield, MA, October 14, 2008.

Lodise TP. High Dose Vancomycin Nephrotoxicity. Presented at the 48th Annual ICAAC/IDSA Meeting, Washington, DC, October 26, 2008.

Lodise TP. Prolonged Infusion Beta-Lactams.

Presented at the 48th Annual ICAAC/IDSA 46th Meeting, Washington, DC, October 27, 2008.

Lodise TP. Human Pharmacodynamics of Effect and Toxicity: Mini-Lecture. Presented at the 48th Annual ICAAC/IDSA 46th Meeting, Washington, DC, October 27, 2008.

Lodise TP. Community-acquired MRSA: What Pharmacists Need to Know. Presented at the ACPE accredited continuing education, Albany College of Pharmacy and Health Sciences, Albany, NY, February 8, 2009.

Lodise TP. When “S” Does Not Mean Success: Looking Beyond Susceptibility When Choosing an Antimicrobial Therapy. Presented at the National Home Infusion Association (NHIA) 2009 Annual Conference Program, Baltimore, MD, March 3, 2009.

Lodise TP. The True Costs of Treating MRSA. Presented at the ACPE/CME accredited continuing education, Seattle, WA, March 26, 2009.

Lodise TP. Applied Antimicrobial Pharmacodynamics: From Bench to Bedside. Presented at the Vermont Society of Health-System Pharmacists Annual CE Meeting, Burlington, VT, April 4, 2009.

>

ACPHS President’s Report 2009

Lodise TP. Optimal Dosing of Beta-lactams: Prolonged Versus Standard Intermittent Infusion in Critically Ill Patients. Presented at the 2009 American College of Clinical Pharmacy and the European Society for Clinical Pharmacy (ACCP/ESCP) International Congress on Clinical Pharmacy, Orlando, FL, April 27, 2009.

Margaret Malone Malone M, Alger-Mayer S. Incidence of vitamin D deficiency after gastric bypass surgery.

Presented at the ACCP 2008 Annual Meeting, Louisville, KY. Malone M, Alger S, Polimeni J. Do patients taking antidepressants have the same one year outcome after gastric bypass surgery?

Presented at the Obesity 27th Annual Scientific Meeting, October 2009.

Macary Marciniak Marciniak MW. Pharmacy Education Update: Residency Programs. Presented at the Albany College of Pharmacy Annual Pharmacy Practice Update, Albany, NY, June 18, 2008.

Christopher Miller Miller CD. Antiretroviral Drug Interactions: What Every Clinician Needs to Know. Presented at the 9th Annual HIV Clinical Care Symposium, Albany, NY, May 29, 2008.

Miller CD. Antiretroviral Therapy Update: Treating in 2008. Presented at the St. Elizabeth’s Hospital: Internal Medicine Grand Rounds, Utica, NY, June 24, 2008.

Miller C. Sexually Transmitted Infections : A Treatment Update. Presented at the NYS Correctional State-Wide Telemedicine Conference, March 18, 2009.

Miller C. HIV Post-Exposure Prophylaxis: Therapy Strategies. Presented at the NYS Correctional State-Wide Telemedicine Conference, May 20, 2009.

Sean Mirk Mirk SM. Your Prescription to Success: A Career in Pharmacy. Presented at the Clawson High School. Clawson, MI, April 24, 2009.

Nimish Patel Patel N, Pallotta K, Grabe DW, Meola S, Hoy C, Drusano GL, Lodise TP. Daptomycin (D) Pharmacokinetics (PK) in Patients (Pts) Receiving Standardized 3X Weekly Hemodialysis (HD). Poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, September 2009.

Patel N, Grifasi, M, Pai M, Rodvold K, Drusano GL, Lodise TP. Vancomycin: We Can Not Get There From Here. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, October 2009.

Patel N, Pallotta K, Grabe DW, Meola S, Hoy C, Drusano GL, Lodise TP. Daptomycin Concentration Time Profile in Hemodialysis Patients .

Presented at the 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, October 2009.

VanDeWal H, Patel N, Tristani L, Grifasi M, Dihmess A, Smith R, Lodise TP. Incidence of Thrombocytopenia Among Veterans’ Affairs Patients that Received Linezolid. Poster Presented at the 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, October 2009.

Sarah Scarpace Adamczyk R, Scarpace SL. Do HMG-CoA reductase inhibitors increase the risk of LFT elevations in patients treated with docetaxel?

Presented at the Hematology/Oncology Pharmacists Association (HOPA)/International Society of Oncology Pharmacy Practitioners (ISOPP) 2008 Joint Annual Conference, Anaheim, CA, June 18-21, 2008.

Scarpace, SL. Head and Neck Cancers Update.

Presented at the Board Certified Oncology Pharmacists (BCOP) Recertification CE program during the Hematology/Oncology Pharmacists Association (HOPA)/International Society of Oncology Pharmacy Practitioners (ISOPP) 2008 Joint Annual Conference, Anaheim, CA, June 18-21, 2008.

Scarpace SL, Dominelli A. Cancer screening, prevention, and early detection course as a vehicle for Roadmap 2015. Presented at the American Association of Colleges of Pharmacy (AACP) annual meeting, Chicago, IL, July 19-23 2008.

Scarpace, SL. Cervical Cancer. Presented at the ACPE-accredited 2-hour CE program presented during the 2008 national Lambda Kappa Sigma convention, Savannah, GA, August 7, 2008.

Scarpace, SL. Overview of “mabs” and “nibs”.

Presented at the ACPE-accredited 1-hour CE program presented to pharmacists at the Roswell Park Pharmacy Oncology Symposium, Niagara Falls Convention Center, Niagara Falls, NY, October 3-4, 2008.

Scarpace, SL. Head and Neck Cancers Update.

Presented at the Board Certified Oncology Pharmacists (BCOP) Recertification CE program presented during the American College of Clinical Pharmacy 2008 Annual Meeting, Louisville, KY, October 21, 2008.

Scarpace, SL. Head and Neck Cancers: A Primer for Pharmacists in Community, Clinical, and Hospital Settings. Presented at the ACPEaccredited 1-hour CE program presented to pharmacists at the Barbara DiLascia Oncology Symposium, Albany College of Pharmacy and Health Sciences, Albany, NY, October 26, 2008.

Scarpace, SL. Targeted Drug Therapy: An Update in Oncology Treatment. Presented at the ACPE-accredited 1-hour CE program presented to pharmacists as part of American Health Resources, Inc., PHARMEd: Continuing Educa-

tion Programs for Pharmacists symposium, Springfield, MA. December 4, 2008.

Scarpace, SL. Head and Neck Cancers Update.

Presented at the Board Certified Oncology Pharmacists (BCOP) Recertification CE program presented during the 2008 American Society of Health-system Pharmacy Midyear Clinical Meeting, Orlando, FL, December 9, 2008.

Scarpace, SL. Targeted Drug Therapy.

Presented at the ACPE-accredited 1-hour CE program presented to pharmacists at the Northeastern New York Society of Healthsystems Pharmacists meeting, Schenectady, NY, February 19, 2009.

Scarpace, SL. Medication Errors in Hematology/Oncology: Tips for Pharmacy Practice.

Presented at the ACPE-accredited 1-hour CE program presented to pharmacists at the Northeastern New York Society of Healthsystems Pharmacists meeting, Schenectady, NY, February 19, 2009.

Scarpace, SL. Targeted Drug Therapy: An Update in Oncology Treatment. Presented at the ACPE-accredited 1-hour CE program presented to pharmacists as part of American Health Resources, Inc PHARMEd: Continuing Education Programs for Pharmacists symposium, Albany, NY, February 25, 2009.

Scarpace SL. Considerations for the Off-label Use of Medications in Oncology. Program presented to law students, faculty, and public guests as part of the Albany Law School Journal of Science and Technology Symposium, Albany, NY, March 27, 2009.

Scarpace SL. Supportive Care Paradigms for Treating Elderly Patients with Cancer. Presented at the ACPE-accredited 30-minute CE program presented to pharmacists at the 2009 American College of Clinical Pharmacy (ACCP)/ European Society of Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy, Orlando, FL, April 26, 2009.

Joanna Schwartz Schwartz J. Novel Agents for Breast Cancer Treatment. Presented at the National Consortium of Breast Cancer Centers, Las Vegas, NV, March 16, 2009.

Schwartz J. Update on Adverse Effect Management for Treatments for Breast Cancer.

Presented at the National Consortium of Breast Cancer Centers, Las Vegas, NV, March 17, 2009.

Schwartz J. Update in New Treatments for Cancer. Presented at the Vermont Society of Health System Pharmacists, Middlebury, VT, May 21, 2009.

Schwartz J. Novel combination chemotherapy for metastatic breast cancer: beating the odds.

Presented at the Hematology Oncology Pharmacist Association, Miami, FL, June 17, 2009.

Aimee Strang Strang AF. Tying it Together: A Non-Prescription Medication Triage and Counseling Assessment. Presented at the Nonprescription Medicines Academy, Cincinnati OH, September 26, 2008.

tive stress and vascular reactivity in CKD patients SPONSOR: Abbott Laboratories CO-INVESTIGATORS: Darren Grabe TOTAL GRANT: $108,000

Strang AF. Your Students and their Patient Counseling Skills. Presented at the Albany College of Pharmacy and Health Sciences, Albany, NY, October 14, 2008.

Pharmaceutical Sciences

Strang AF. The First Few Years of Teaching.

Presented at the Albany College of Pharmacy and Health Sciences Faculty Development Session, Albany, NY, October 24, 2008.

Gr ants Thomas Lodise PROJECT: Comparing Outcomes for Daptomycin, Vancomycin, and Linezolid in the Outpatient Setting SPONSOR: Cubist Pharmaceuticals Inc. CO-INVESTIGATOR: Leon Cosler TOTAL GRANT: $150,000 PROJECT: Comparing Outcomes for Daptomycin, Vancomycin, and Linezolid in the Outpatient Setting SPONSOR: Cubist Pharmaceuticals Inc. CO-INVESTIGATORS: Leon Cosler, Nimish Patel TOTAL GRANT: $150,406.00 PROJECT: Epidemiology of Vancomycin Susceptibility Phenotypes Associated with Suboptimal Clinical Outcomes Among Patients MRSA Bloodstream Infections in Upstate New York SPONSOR: Upstate New York Consortium for Healthcare Research and Quality and the Upstate New York Translational Research Network Pilot Research Grant TOTAL GRANT: $48,225.00 PROJECT: Molecular and Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae SPONSOR: Merck & Co, Inc. CO-INVESTIGATOR: Nimish Patel TOTAL GRANT: $30,625 PROJECT: Ertapenem Pharmacokinetics in Patients on Continuous Ambulatory Peritoneal Dialysis SPONSOR: Merck & Co, Inc. CO-INVESTIGATORS: Katie Pallotta Cardone, Darren Grabe, Nimish Patel TOTAL GRANT: $113,297.50 Margaret Malone PROJECT: A pilot study of the efficacy of Orlistat in the management of pre operative weight loss for bariatric surgery SPONSOR: Research Award funded by GSK Consumer HealthCare TOTAL GRANT: $25,000 Amy Barton Pai PROJECT: Effects of 19-nor-1a-dihydroxyvitamin D2 (paricalcitol) versus placebo on oxida-

P u b l i c at io n s Richard Dearborn Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Voigt JM, Dearborn RE. The tumor suppressor, vitamin D3 up-regulated protein 1 (VDUP1), functions downstream of REPO during Drosophila gliogenesis. Dev Biol. 2008 Mar 15;315:489-504.

Levendusky M, Basle J, Chang S, Mandalaywala NV, Voigt JM, Dearborn RE. Expression and regulation of vitamin D3 up-regulated protein 1 (VDUP1) is conserved in mammalian and insect brain. J Comp Neurol. 2009. (In Press).

Carlos Feleder Yilmaz MS, Goktalay G , Millington WR, Myer BS, Cutrera RA, Feleder C. Lipopolysaccharide-induced hypotension is mediated by a neural pathway involving the vagus nerve, the nucleus tractus solitarius and alpha-adrenergic receptors in the preoptic anterior hypothalamic area. J Neuroimmunol. 2008;203:39-49.

O’Donnell P, Tseng KY, Feleder C. Altered dopaminergic modulation of GABA and glutamate cortical transmission in a developmental animal model of schizophrenia. Biol Psychiatry.

2008;63:233-234.

O’Donnell P, Tseng KY, Feleder C. Altered D2 modulation of prefrontal cortical interneurons in developmental animal models of schizophrenia. Schizophr Res. 2008;102:12-13.

O’Donnell P, Tseng KY, Feleder C. Periadolescent emergence of impaired dopamine modulation of prefrontal GABA circuits in developmental animal models of schizophrenia. Int J Neuropsychopharmacol. 2008;11:11-12.

Yilmaz MS, Millington WR, Feleder C. The preoptic anterior hypothalamic area mediates initiation of the hypotensive response induced by lipopolysaccharide in male rats. Shock.

2009;29:232-237.

O’Donnell P, Tseng KY, Feleder C. Neonatal intra-hippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats. J Neurosci. 2009. (In Press).

Villanueva A, Yilmaz MS, Millington WR, Cutrera RA, Stouffer DG, Parsons LH, Cheer JF, Feleder C. Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock.

2009. (In Press).

35

Gail Goodman-Snitkoff Goodman- Snitkoff G, Hubbard A, Broders J, Schuna AA. Immunity and Autoimmune Disease. In: Calis K, Hansen L, O’Connell MB, Smith J, eds. Woman’s Health Text. Bethesda, MD. American Society of Health System Pharmacists; 2009.

Goodman-Snitkoff G. Immunology. In: Shargel L, ed. Comprehensive Pharmacy Review. 7th Ed. Philadelphia, PA:Lippincott, Williams and Wilkins; 2009. (In Press).

Goodman-Snitkoff G. Microbiology. In: Shargel L, ed. Comprehensive Pharmacy Review. 7th Ed. Philadelphia, PA. Lippincott, Williams and Wilkins; 2009. (In Press).

Arnold Johnson Lin WY, Mannikarottu A, Chichester P, Guven A, Johnson A, Neumann P, Juan YS, Schuler C, Kogan BA, Levin RM. Changes in the smooth muscle of the corpora cavernosum related to reversal of partial outlet obstruction in rabbits.

J Androl. 2008;29:164-171.

Kalorin C, Mannikarottu A, Neumann P, Leggett RE, Weisbrot J, Johnson A, Kogan BA, Levin RM. Protein oxidation as a novel biomarker of bladder decompensation. Br J Urol.

2008;102:495-499.

Johnson A. TNF induced activation of pulmonary microvessel endothelial cells: a role for GSK3β. Am J Physiol. 2009;96:L700–L709.

Robert Levin Juan YS, Mannikarottu A, Schuler S, Lin WY, Huang CH, Levin RM. The immediate effect of nitric oxide on the rabbit bladder after ovariectomy. Nitric Oxide. 2008;19:289-294.

Juan YS, Levin RM, Chuang SM, Hydery T, Li S, Kogan B, Schuler C, Huang CH, Mannikarottu A. The beneficial effect of coenzyme Q10 and alpha lipoic acid on obstructive bladder dysfunction in the rabbit. J Urol. 2008;180:2234-2240.

Lin WY, Mannikarottu A, Chichester P, Neumann P, Juan, YS, Perez-Martinez FC, Levin RM. The effect of chronic partial bladder outlet obstruction on corpus cavernosum smooth muscle and rho-kinase in rabbits. Neuroruol Urodyn. 2008;27:826-831.

Onal B, Levin RM, Kogan BA, Guven A, Leggett R, Mannikarottu AS. Novel alterations in superoxide dismutase and catalase activities in the female rabbit bladder subjected to hormonal manipulations. Int Urol Nephrol. 2008;39:10491054.

Chou E, Whitbeck C, Borow A, Burden O, Mays P, Levin RM. The effect of intravesical ketoprofen on ach-evoked urinary bladder contractility and hyperreflexia in the anesthetized rabbit model. Int Urol Nephrol. 2008;39:1055-1059.

Lin WY, Guven A, Juan YS, Neumann P, Whitbeck C, Chichester P, Kogan B, Levin RM, Mannikarottu A. Free radical damage

>

ACPHS President’s Report 2009

Juan YS, Hydery T, Mannikarottu A, Lin WY, Kogan B A, Whitbeck C, Leggett RE, Levin RM. Coenzyme Q10 protect against ischemia/ reperfusion induced biochemical and functional changes in rabbit urinary bladder. Mol Cell Biochem. 2008;311:73-80.

Matsumoto S, Hanai T, Uemura H, Levin RM. Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. BJU Int. 2009;103:987-990.

Lopes LB, Flynn CR, Komalavilas P, Panitch A, Brophy CM, Seal BL. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP kinase 2 inhibitor. Biochem Biophys Res Commun. 2009;382:535-539.

Hass MA, Nichol P, Lee L, Levin RM. Estrogen modulates permeability and prostaglandin levels in the rabbit urinary bladder. Prostaglandins Leukot Essent Fatty Acids. 2009;80:125-129.

Nornoo A, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: in-situ and pharmacokinetic studies. Eur J Pharm Biopharm. 2009;71:310-317.

Perez-Martinez FC, Mannikarottu A, Guven A, Johnson A, Chichester P, Juan YS, Lin WY, Levin RM. Expression of parathyroid hormonerelated protein in the partially obstructed rabbit bladder. Urol Int. 2008;81:82-86.

Juan YS, Li S, Levin RM, Kogan BA, Schuler C, Leggett RE, Huang CH, Mannikarottu A. The effect of ischemia/reperfusion on rabbit bladder - role of rho-kinase and smooth muscle regulatory proteins. Urology. 2009;73:1126-1130.

Levin RM, Leggett RE, Whitbeck C, Matsumoto S, Ohto N, Ikeda T, Mizutani K. Kohki tea protects the rabbit bladder from ischemia/reperfusion induced contractile dysfunction. Urol Int. 2008;80:425-430.

Juan YS, Chuang SM, Mannikarottu A, ChunHsung H, Schuler C, Levin RM. Coenzyme Q10 diminishes ischemia-reperfusion induced apoptosis and nerve injury in rabbit urinary bladder. Neurourol Urodyn. 2009. (In Press).

Lopes LB, Furnish EJ, Komalavilas P, Flynn CR, Ashby P, Hansen A, Ly DP, Yang GP, Longaker MT, Panitch A, Brophy CM. Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. J Invest Dermatol. 2009;129:590-598.

Siflinger-Birnboim A, Levin RM, Hass MA. Partial outlet obstruction of the rabbit urinary bladder induces selective protein oxidation.

Neurourol Urodyn. 2008;27:532-539.

Juan YS, Mannikarottu A, Chuang SM, Li S, Lin AD, Chang-Chou L, Schuler C, Leggett R, Levin RM. Protective effect of antrodia camphorata on bladder ischemia/reperfusion injury. Int Urol Nephrol. 2009. (In Press).

as a biomarker of bladder dysfunction after partial outlet obstruction and reversal. BJU Int. 2008;101:621-626.

Lin WY, Rehfuss A, Whitbeck C, Levin RM. Effect of coenzyme Q10 and α-lipoic acid on the response of the rabbit urinary bladder to repetitive stimulation and in vitro ischemia.

Urology. 2008;72:214-219.

Levin RM, Juan YS, Whitbeck C, Perez-Martinez FC, Lin WY. The effect of darifenacin on overactive bladder in female and male rabbits. Int Urol Nephrol. 2008;40:303-309.

Lin WY, Mannikarottu A, Chichester P, Guven A, Johnson A, Neumann P, Juan YS, Schuler C, Kogan BA, Levin RM. Changes in the smooth muscle of the corpora cavernosum related to reversal of partial outlet obstruction in rabbits.

J Androl. 2008;29:164-171.

Chughtai B, Levin RM, Chichester P, Schuler C, Leggett R, Mannikarottu A, De E. Ischemic etiology of incontinence in women, a theory and a review. Open Urol Nephrol J. 2008;1:1-8.

Lin WY, Radu F, Schuler C, Leggett R, Mannikarottu A, Levin RM. Effect of ovariectomy and estrogen therapy on the free fatty acid content, endogenous lipase activity, and phospholipid content of the rabbit urinary bladder.

BJU Int. 2008;102:885-889.

Lin WY, Mannikarottu A, Li S, Juan J, Leggett R, Strassner J, Sokol R, Schuler C, Javed Z, Kogan B, Levin RM. Estrogen administration attenuates bladder outlet obstruction-induced oxidative stress in female rabbit. Neuroruol Urodyn. 2009;28:95-100.

Bean H, Radu F, De E, Schuler C, Leggett RE, Levin RM. Comparative evaluation of antioxidant reactivity within obstructed and control rabbit urinary bladder tissue using FRAP and CUPRAC assay. Mol Cell Biochem.

2009;323:139-142.

Lin WY, Mannikarottu A, Li S, Juan YS, Schuler C, Javed Z, Blaivas J, Levin RM. In-Vivo correlation of blood flow measurements with bladder function. World J Urol. 2009. (In Press).

Li S, Juan YS, Kogan BA, Mannikarottu A, Leggett RE, Schuler C, Levin RM. Effects of inosine on in-vitro hypoxia in the absence of substrate on bladder dysfunction in adult rats. Urology.

2009. (In Press).

Matsumoto S, Shimizy N, Hanai T, Uemura H, Levin RM. Bladder outlet obstruction accelerates bladder carcinogenesis. BJU Int. 2009. (In Press).

Li S, Hydery T, Juan YS, Lin WY, Kogan BA, Mannikarottu A, Leggett R, Schuler C, Levin RM. The effect of chronic ovariectomy on female rabbit urinary bladder function. Urology. 2009.

(In Press).

Juan YS, Chuang SM, Kogan BA, Mannikarottu A, Huang CH, Li S, Leggett R, Schuler C, Levin RM. Effect of ischemia/reperfusion on bladder nerve and Detrusor cell damage. Int Urol Nephrol. 2009. (In Press).

Luciana Lopes Lopes LB, Furnish E, Komalavilas P, Seal BL, Panitch A, Bentley MV, Brophy CM. Enhanced skin penetration of P20 phosphopeptide using protein transduction domains. Eur J Pharm.

Biopharm. 2008;68:441-445.

Komalavilas P, Penn RB, Flynn CR, Thresher J, Lopes LB, Furnish EJ, Guo M, Pallero MA, Murphy-Ullrich JE, Brophy CM. The small heat shock-related protein, HSP20, is a cAMP-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. Am J Physiol Lung Cell Mol Physiol. 2008;294:L69-L78.

Lopes LB, Murphy N, Nornoo A. Enhancement of transdermal delivery of progesterone using medium-chain mono and diglycerides as skin penetration enhancers. Pharm Dev Technol. 2009.

William Millington Yilmaz MS, Millington WR, Feleder C. The preoptic anterior hypothalamic area mediates initiation of the hypotensive response induced by lipopolysaccharide in male rats. Shock.

2008;29:232-237.

Yilmaz MS, Göktalay G, Myer BS, Millington WR, Cutrera R, Feleder C. Lipopoly-saccharide-induced hypotension is mediated by a neural pathway involving the vagus nerve, the nucleus tractus solitarius and alpha-adrenergic receptors in the preoptic anterior hypothalamic area. J Neuroimmunol. 2008;203:39-49.

Millington WR, Göktalay G. Neurochemical approaches to addiction treatment. In: Smith H, Passik S, eds. Pain and Chemical Dependency.

NY: Oxford University Press; 2008.

Villanueva A, Yilmaz MS, Millington WR, Cutrera RA, Stouffer DG, Parsons LH, Cheer JF, Feleder C. Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock.

2009. (In Press).

Alexandre Steiner Steiner AA, Oliveira DL, Roberts JL, Petersen SR, Romanovsky AA. Nicotine administration and withdrawal affect survival in systemic inflammation models. J Appl Physiol.

2008;105:1028-1034.

Ootsuka Y, Blessing WW, Steiner AA, Romanovsky AA. Fever response to intravenous prostaglandin E2 is mediated by the brain but does not require afferent vagal signaling. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1 294-R1303.

Steiner AA, Krall CM, Liu E. A reappraisal on the ability of leptin to induce fever. Physiol Behav. 2009;97:430-436.

Jeffrey Voigt Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Voigt JM, Dearborn RE. The tumor suppressor, vitamin D3 up-regulated protein 1 (VDUP1), functions downstream of REPO during drosophila gliogenesis. Dev Biol.

2008;315:489-504.

Levendusky M, Basle J, Chang S, Mandalaywala NV, Voigt JM, Dearborn RE. Expression and regulation of vitamin D3 up-regulated protein 1 (VDUP1) is conserved in mammalian and insect brain. J Comp Neurol. 2009. (In press).

M. Sertac Yilmaz Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E, Ulus IH. Peripheral administration of CDP-choline and its cholinergic metabolites increases serum insulin: peripheral muscarinic and nicotinic acetylcholine receptors are both involved in its action. Neurosci Lett. 2008;431:71-76.

Haian Zheng Nornoo A, Zheng H, Lopes L, Johnson-Restropo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: in-situ and pharmacokinetic studies.

Eur J Pharm Biopharm. 2009;71:310-317.

A b s t r a c t s / P r e s e n tat io n s Richard Dearborn Dearborn RE, Basle J, Mandalaywala NV, Chang S, Levendusky MC, Voigt JM. Glucose regulates expression of the tumor suppressor VDUP1 in mammalian and insect brain. Society for Neuroscience, Washington, DC, November 2008.

Voigt JM, D’Alessandro M, Leonardi P, Dearborn RE. Regulation of VDUP-1 expression in glioma (U-87) cells by glucose. American Association for Cancer Research, Denver, CO, April 2009.

Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus I. Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations.

Auton Autacoid Pharmacol. 2008;28:41-58.

Li HT, Lopes LB, Zheng H, Hass MA, Voigt J, Dearborn R. Research-based instructional style for pharmaceutical analytical techniques, American Association of Colleges of Pharmacy, Boston, MA, July 2009.

Yilmaz MS, Millington WR, Feleder C. The preoptic anterior hypothalamic area mediates initiation of the hypotensive response induced by lipopolysaccharide in male rats. Shock.

2008;29:232-237.

Carlos Feleder Feleder, C. The preoptic anterior hypothalamic neuronal ensamble initiates bacterial hypotension during septic shock. University of La Plata, School of Pharmacy, Department of Physiology.

Buenos Aires, Argentina, December 2008.

Yilmaz MS, Coskun C, Yalcin M, Mutlu D, Savci V. Hypotensive effects of intravenously administered uridine and cytidine in conscious rats: the involvement of adenosine receptors. Eur J Pharmacol. 2008;584:125-136.

Yilmaz MS, Coskun C, Yalcin M, Savci V. The protective effect of CDP-choline in short term myocardial ischemia reperfusion injury in rats is mediated by central cholinergic muscarinic activation. Naunyn Schmiedeberg’s Arch Pharmacol. 2008;378:293-301.

Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus IH. Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: involvement of the peripheral autonomic nervous system. Eur J Pharmacol. 2008;589:315-322.

Yilmaz MS, Göktalay G , Millington WR, Myer BS, Cutrera RA, Feleder C. Lipopolysaccharide-induced hypotension is mediated by a neural pathway involving the vagus nerve, the nucleus tractus solitarius and alpha-adrenergic receptors in the preoptic anterior hypothalamic area. J Neuroimmunol. 2008;203:39-49.

Villanueva A, Yilmaz MS, Millington WR, Cutrera RA, Stouffer DG, Parsons LH, Cheer JF, Feleder C. Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock.

2009. (In Press).

Feleder, C. Endocannabinoids in the preoptic anterior hypothalamic area initiates bacterial hypotension during septic shock. Universidad de Santiago de Compostela, School of Pharmacy, Sanitago de Compostela, Spain, February 2009.

Feleder C, Vit P, Blatteis CM. Preoptic nitric oxide modulates endotoxic fever by controlling local norepinephrine activity. Experimental Biology, New Orleans, LA, April 2009.

Yilmaz MS, Villanueva A, Millington WR, Cutrera R, Cheer JF, Feleder C. Central rimonabant administration prevents endotoxic hypotension by inhibiting norepinephrine release in the preoptic anterior hypothalamic area. Experimental Biology, New Orleans, LA, April 2009.

Robert Levin Levin, R. Effect of cyclic estrogen on the female rabbit urinary bladder. Albany Medical College, Division of Urology, October 2008.

Levin, R. Use of natural products in the treatment of obstructive bladder dysfunction.

Zheng-Zhaou, China, November 2008.

Levin, R. Current topics in urological research.

Zheng-Zhaou, China, November 2008.

Levin R. Obstructed bladder dysfunction.

Symposium on Antrodia Camphorata. Taipei, Taiwan, March 2009.

37

Levin R. Female bladder dysfunction. Symposium on Antrodia Camphorata. Taipei, Taiwan, March 2009.

Hydery T, Levin RM. Mechanism of the protective effect of coenzyme Q10 and alpha lipoic acid on obstructive urinary bladder dysfunction.

New England Science Symposium, Boston, MA, April 2009.

Rehfuss A, Schuler C, Juan YS, Levin RM. Further studies on the effect of cyclical estrogen on bladder function following ovariectomy.

American Urological Association, Chicago, IL, April 2009.

Radu F, Bean H, Schuler C, Leggett R, Levin RM. Comparative Evaluation of Antioxidant Reactivity between Ovariectomized and Control Bladder Tissue using FRAP and CUPRAC assays. American Urological Association, Chicago, IL, April 2009.

Bean H, Radu F, De E, Schuler C, Leggett R, Levin RM. Comparative evaluation of antioxidant reactivity within obstructed and control bladder tissue using FRAP and CUPRAC assays. American Urological Association, Chicago, IL, April 2009.

Venugopal V, Radu F, Leggett R, Abraham C, Schuler C, Levin RM. Effect of hydrogen peroxide on citrate synthase activity of the rabbit urinary bladder in the presence and absence of a standardized grape suspension. American Urological Association, Chicago, IL, April 2009.

Bean H, Leggett R, Levin RM. Antioxidant levels of common fruits and juices: potential for treating obstructive bladder dysfunction. American Urological Association, Chicago, IL, April 2009.

Hydery T, Schuler C, Levin RM. Mechanism of the protective effect of coenzyme Q10 and alpha lipoic acid on obstructive urinary bladder dysfunction. American Association of Pharmaceutical Scientists. Rocky Hill, CT, April 2009.

Hydery T, Schuler C, Levin RM. Mechanism of the protective effect of coenzyme Q10 and alpha lipoic acid on obstructive urinary bladder dysfunction. New England Science Symposium, Boston, MA, April 2009.

VanDeWall H, Li HT, Venugopal V, Li HK, Naydin S, Ramani R, Zheng H, Levendusky M, Hass M, Levin RM, Bentley V, Lopes L. Development and evaluation of microemulsions for topical delivery of an antioxidant molecule, lycopene.

American Association of Pharmaceutical Scientists, Rocky Hill, CT, April 2009.

Levin R. Chinese urological symposium: effect of antrodia on obstructive bladder dysfunction.

American Urological Association, Orlando, FL, May 2009.

Ercolani M, Levin RM. The effects of cystinuria on bladder contractility and histology in the Slc3a1 knockout mouse– new insights for the management of pediatric cystinuria. American Association of Pediatrics, June 2009.

>

ACPHS President’s Report 2009

Luciana Lopes Lopes LB, Nornoo AO. Use of capmul MCM as a skin penetration enhancer: influence of capmul concentration and vehicle. Controlled Release Society, New York, NY, July 2008.

VanDeWall H, Li HT, Venugopal V, Li HK, Naydin S, Ramani R, Zheng H, Levendusky M, Hass MA, Levin R, Bentley MV, Lopes LB. Development and evaluation of microemulsions for topical delivery of an antioxidant molecule, lycopene.

American Association of Pharmaceutical Scientists, Rocky Hill, CT, April 2009.

Hosmer J, Nornoo A, Lopes LB. Development of BRIJ-based liquid crystalline phases as topical delivery systems for paclitaxel. American Association of Pharmaceutical Scientists, Rocky Hill, CT, April 2009.

William Millington Cavun S, Filiz N, Buyukuysal RL, Millington WR. Glycyl-L-glutamine inhibits the rise in extracellular dopamine and DOPAC concentrations evoked by acute morphine administration in the nucleus accumbens. IX World Conference on Clinical Pharmacology and Therapeutics, Québec City, Québec, Canada, July-August 2008.

Filiz N, Buyukuysal RL, Millington WR, Cavun S. The effect of centrally injected glycyl-L-glutamine on extracellular dopamine and DOPAC concentrations in the nucleus accumbens after chronic morphine administration. IX World Conference on Clinical Pharmacology and Therapeutics. Québec City, Québec, Canada, July-August 2008.

Yilmaz MS, Villanueva A, Millington WR, Cutrera RA, Cheer JF, Feleder C. Central rimonabant administration prevents endotoxic hypotension by inhibiting norepinephrine release in the preoptic anterior hypothalamic area. Experimental Biology, New Orleans, LA, April 2009.

Alexandre Steiner Steiner AA, Krall CM, Liu E. Can leptin induce fever? Experimental Biology, New Orleans, LA, April 2009.

Jeffrey Voigt Dearborn RE, Basle J, Mandalaywala NV, Chang S, Levendusky MC, Voigt JM. Glucose regulates expression of the tumor suppressor VDUP1 in mammalian and insect brain. Society for Neuroscience, Washington, DC, November 2008.

Voigt JM, D’Alessandro M, Leonardi P, Dearborn RE. Regulation of VDUP-1 expression in glioma (U-87) cells by glucose. American Association for Cancer Research. Denver, CO, April 2009.

Li HT, Lopes LB, Zheng H, Hass MA, Voigt JM, Dearborn RE, Millington WR. Research-based instructional style for pharmaceutical analytical techniques. American Association of Colleges of Pharmacy. Boston, MA, July 2009.

M. Sertac Yilmaz Yilmaz MS, Villanueva A, Cheer J, Millington WR, Feleder C. Central rimonabant administration prevents endotoxic hypotension by inhibiting norepinephrine release in the preoptic anterior hypothalamic area. Experimental Biology, New Orleans, LA, April 2009.

Haian Zheng Wong P, Policastro C, Bluestein L, Zheng H. Pharmaceutics online-homework: calculation practice and evaluation in large-class.

American Association of Colleges of Pharmacy, Chicago, IL, July 2008.

VanDeWall H, Li HT, Venugopal V, Li HK, Naydin S, Ramani R, Zheng H, Levendusky M, Hass MA, Levin RM, Bentley VLB, Lopes LB. Development and evaluation of microemulsions for topical delivery of an antioxidant molecule, lycopene.

American Association of Pharmaceutical Scientists, Rocky Hill, CT, April 2009.

Gr ants Carlos Feleder PROJECT: The Role of the Spleen in the Febrile Response SPONSOR: NIH (R15) TOTAL GRANT: $150,000 PROJECT: The Central Nervous System Mediates Hypotension During Septic Shock SPONSOR: American Foundation for Pharmaceutical Education TOTAL GRANT: $5,000 PROJECT: Prenatal Stress Affects the Infant Immune Response in Adult Rats SPONSOR: University of Buenos Aries, Argentina TOTAL GRANT: $40,000 PROJECT: Central Mechanisms that Mediate Hypotension During Sepsis: From Brain to Periphery SPONSOR: ACPHS Scholarship of Discovery and Educational Excellence Grant Program TOTAL GRANT: $4,970 Arnold Johnson PROJECT: A Mechanism for TNF Induced Endothelial Dysfunction SPONSOR: NIH (R01) TOTAL GRANT: $800,000 Robert Levin PROJECT: Effects of Solifenacin Alone or in Combination with Antioxidants in the Treatment of Experimental Overactive Bladder Dysfunction in Rabbits SPONSOR: Astellas Pharma Global Development TOTAL GRANT: $83,000 PROJECT: Time Course of the Effects of Vaginally Delivered Oxybutynin on Bladder and Systemic Cholinergic Function SPONSOR: FemmePharma TOTAL GRANT: $9,875

Luciana Lopes PROJECT: Enhancement of Topical Delivery of Paclitaxel Using Liquid Crystalline Phases SPONSOR: Scholarship of Discovery, Albany College of Pharmacy and Health Sciences TOTAL GRANT: $10,000 Alexander Steiner PROJECT: Hypothermia in Severe Sepsis: Could it be Beneficial?

SPONSOR: Albany College of Pharmacy and Health Sciences Scholarship of Discovery Grant TOTAL GRANT: $5,000 Jeffrey Voigt PROJECT: Regulations of VDUP1 Expression in Human Breast Tumor Cells by the Hedgehog Pathway SPONSOR: Albany College of Pharmacy and Health Sciences Intramural Grant TOTAL GRANT: $5,000 Haian Zheng PROJECT: Detection of Penicillins from Various Drug Products SPONSOR: New York State Office of Attorney General TOTAL GRANT: $6,000

Margaret Carroll Carroll, M. Review essay of Alice McDermott’s After This, Irish Literary Supplement. Irish Literary Supplement. 2008.

Carroll, M. The Road Away Becomes the Road Back: Prodigal Sons in the Short Stories of John McGahern. Journal of the Short Story in English: Special Issue on John McGahern.

Carroll, M. Review essay of John McGahern’s Creature of the Earth. The Canadian Journal of Irish Studies.

Daniel d’Oney d’Oney, D. Food as Bridge and Barrier: The Houma and Foodways of Southern Louisiana.

Louisiana Cultural Vistas. 2008;19:3. d’Oney, D. Watered by Tempests: Hurricanes in the Cultural Fabric of the United Houma Nation.

American Indian Culture and Research Journal.

2008;32(2):11-26. d’Oney, D. Creating the Big Easy: New Orleans and the Emergence of Modern Tourism, 19181945. Southern Studies: An Interdisciplinary Journal of the South. 2009;16(1).

PROJECT: Mechanisms by which Oral Ingestion of Grape Suspensions Protect Mitochondria from Ischemic/Reperfusion Damage SPONSOR: California Grape Commission TOTAL GRANT: $30,000

Lynn Evans Evans, LM, Myers, MM, Monk, CE. Pregnant Women’s Cortisol is Elevated with Anxiety and Depression- But Only When Comorbid. Archives of Women’s Mental Health. 2008;11(3):239-248.

PROJECT: Enhancement of Topical Delivery of Paclitaxel Using Liquid Crystalline Phases SPONSOR: Scholarship of Discovery, Albany College of Pharmacy and Health Sciences Intramural Grant TOTAL GRANT: $10,000

Martha Hass Hass, M. A Practical Approach to Teaching Resonance in Introductory Organic Chemistry.

Chem. Educator. 2008;13(3):136-140.

Arts and Sciences P u b l i c at io n s James Anderson Anderson, J. The Psychological Robot: A New Tool for Learning. The International Journal of Teaching and Learning in Higher Education.

2007;19(3).

Patricia Baia Baia, P. The Role of Commitment to Pedagogical Quality. The Adoption of Instructional Technology in Higher Education. 2009.

Kenneth Blume Blume, K, Coy F, Cross II. Lincoln’s Man in Liverpool. International Journal of Maritime History.

2008 Jun;438.

Blume, K. Southern Pacific Water Lines: Marine, Bay & River Operations of the Southern Pacific System. Journal of the Steamship Historical Society of America. 2008;80.

Hass, M, Nichol, P, Lee, L, Levin, R. Estrogen Modulates Permeability and Prostaglandin Levels in the Rabbit Urinary Bladder. Prostaglandins, Leukotrienes and Essential Fatty Acids.

2009;80(2):125-129.

Marion Jacobson Jacobson, M. “The Accordion and the Body Politic: Val-Taro Musette and the Negotiation of Northern Italian American Identity in Manhattan.” In Joseph Sciorra, ed. Italians in the Americas. (In Press).

Jacobson, M. Accordions, Commodities, and Differences. World of Music. 2008;3.

Jacobson, M. The Wanderer. Journal of the Society for American Music. 3(1):120-121.

Jacobson, M. Complete Works of Pietro Deiro, 1890-1950. Journal of the Society for American Music. 3(1):119-120.

Kevin Hickey Hickey, K. Exiles Must Make Their Own Maps: Space, Teleology, and Derek Walcott. International Journal of the Humanities. 2008;6.7:85-96.

Dudley Moon Moon, D. Herbal Products and Botanicals.

In: Pharmacy Practice for Technicians. 4th ed.

New York: Delmar Publishers; 2008.

Erika Muse Muse, E. Chinese American Christian Women of New England: Transformation and Continuity in Inter-Generational Narratives of Living in Christ. In: Encountering the Text: Cross-Cultural Perspectives on Biblicism. New Jersey: Rutgers University Press;2009:189-222.

Michael Pittman Pittman, M. G.I. Gurdjieff: Armenian Roots, Global Branches. Cambridge: Cambridge Scholars Press;2009.

Laura Rogers Rogers, L. Finding Our Way from Within: Critical Pedagogy in a Prison Writing Class. Open Words: Access and English Studies. 2008;2(1):22-48.

Michael Racz Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park S.J, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies. Circulation. 2009;119:3198-206.

Saleh SS, Racz M, Hannan E. The Effect of Preoperative and Hospital Characteristics on Costs for Coronary Artery Bypass Graft. Annals of Surgery. 2009;249:335-41.

A b s t r a c t s / P r e s e n tat io n s Patricia Baia Baia, P. The Role of Commitment to Pedagogical Quality: The Adoption of Instructional Technology in Higher Education. CIT, 2009.

Baia, P. Birds of a feather…Prosper together.

Capital District Educational Technology Group, CIT, 2009.

Baia, P. Instructional Technology Adoption Models in Higher Ed. PETE & C, 2009.

Kenneth Blume Blume, K. African-American Identities and America’s Foster Child: African Americans and the Liberian “Homeland,” 1865-1915. Fifth Black Atlantic Community Conference, Central State University, Wilberforce, OH, April 17, 2008.

Margaret Carroll Carroll, M. Conflict, Coexistence, and Community in John McGahern’s Creatures of the Earth.

National meeting of the American Conference of Irish Studies, St. Ambrose University, Davenport, IA, April 16-19, 2008.

Carroll, M. Making Albany New York Irish: Bishop John McCloskey, 1847-1864. International meeting of the American Conference for Irish Studies, National University of Ireland, Galway, June 10-13, 2009.

39

Ray Chandrasekara Chandrasekara, R. Renegotiating the Sublime: Islamic Transformation in the Malay World.

New York Conference on Asian Studies, Hamilton College, NY, September 26-27, 2008.

Chandrasekara, R. China in Southeast Asia: Expanding the Strategic Periphery. 18th Annual Asia Network Conference, Atlanta, GA, March 13-15, 2009.

Daniel d’Oney d’Oney, D. Piles of Memories: Hurricane Katrina and Native Peoples of Louisiana.

American Studies Association, Albuquerque, NM, October 2008.

Martha Hass Hass, M. Qualitative and Quantitative Analysis of Phospholipids by TLC-ATR-FTIR. American Oil Chemists Society, 100th Annual Meeting.

Orlando, FL, May 2009.

Kevin Hickey Hickey, K. Exiles must make their own maps: Space, Teleology, and Derek Walcott. Sixth International Conference on New Direction in the Humanities, Istanbul, Turkey, July 15-18, 2008.

Hickey, K. Four Years across Africa by Bike.

35th Annual African Literature Association (ALA) Conference, University of Vermont, April 16, 2009. Northwest College, Powell, WY, May 27, 2008. Union College Schenectady, NY, October 29, 2008. State University of New York at Albany, November 14, 2008.

Hickey, K. The Soaring Swifts and Cosmopolitan Geographies of Derek Walcott. 35th Annual New York African Studies Association (NYASA) Conference on Peace and Transformation in the Pan African World in the 21st Century, Syracuse University, NY, April 4, 2009.

Hickey, K. No Black Male Show: Carl Hancock Rux and the Heritage of Black Performance. African Literature Association (ALA) Conference on Africa and Blackness in World Literature and Visual Arts, University of Vermont, Burlington, April 17, 2009.

Marion Jacobson Jacobson, M. Italian Dance Hall Culture: Italian Americans, Accordions, and a Pluralistic Vision of Ethnicity in Manhattan, 1938-1961. Italians in the Americas Conference, John D. Calandra Institute for Italian Studies, Queens College, Queens, New York, April 25, 2008.

Jacobson, M. The Globalization of the Accordion. Organized panel on the Accordion, the International Council on Traditional Music, Vienna, Austria, July 7-11.

Jacobson, M. Xtreme Combo: Re-imagining the Diatonic Button Accordion as a Cultural Technology in the Texas-Mexican Borderlands.

Society of American Music, Denver, CO, March 19, 2009.

ACPHS President’s Report 2009

Dudley Moon Moon, D. Statin Drugs and Isoprenoid Lipids.

Nature-ceuticals Symposium, Albany College of Pharmacy and Health Sciences, Albany, NY, 2008.

Moon, D. From Leeches to Thrombin-Targeted Drugs. Nature-ceuticals Symposium, Albany College of Pharmacy and Health Sciences, Albany, NY, 2008.

Erika Muse Muse, E. New England through Kingdom Eyes: Multiculturalism and its significance for defining the Chinese Christian Community. APARRI, August 8-10, 2008.

Muse, E. From Theory to Practice: Building Competencies in Intercultural Encounters in Asian America. Association for Asian American Studies.

Michael Pittman Pittman, M. Creating New Discourses in Western Esotericism: 21st Century Reflections on the Reconstruction of Sufism in the Work of G.I. Gurdjieff. American Academy of Religion Conference, Chicago, Illinois, November 1, 2008.

Pittman, M. Problematizing East-West Essentialisms: Discourse, Authorhood, and Identity Crisis in Orhan Pamuk’s The White Castle.”

American Comparative Literature Association Conference, Harvard University, March 30, 2009.

Pittman, M. The Films of Majid Majidi: Iranian Cinematic Poetics and the Spiritual Poverty of Rumi. American Academy of Religion Regional Conference, Le Moyne University, Syracuse, NY, May 1, 2009.

Laura Rogers Rogers, L. Pools of Sorrow, Waves of Joy: Across the Universe of a Prison Writing Workshop. Conference on College Composition and Communication, San Francisco, CA, March 11-14, 2009.

Ex h ibi t io n s Sunanda Sukumar Sukumar, S. Docking Studies of Dipeptides to Metabotropic Glutamate Receptors. 37th Northeast Regional Meeting, June 2008.

Lynn Evans Evans, L, Leotti, L, Werner, E, Westphal, T, Monk, C. Pregnancy-Related Stress Predicts Mothers’ Reports of CBCL Emotional and Behavioral Problems in PreSchoolers. The 2009 Society for Research in Child Development Biennial Meeting, Denver, CO, March 2009.

Martha Hass Hass, M, Levin, RM, Effect of Lipid Peroxides on Phospholipase Activity in the Urinary Bladder.

American Oil Chemists Society, 100th Annual Meeting, Orlando, FL, May 2009.

Gr ants Carlos Feleder PROJECT: The Role of the Spleen in the Febrile Response SPONSOR: National Institute of Allergies and Infectious Diseases (NIH) TERM: 04/01/08-03/31/2011 TOTAL GRANT: $231,000 Susan Ludeman PROJECT: Pharmacology of Cyclophosphamide and Other Alkylators SPONSOR: National Cancer Institute (NIH; R01) TERM: 03/12/09-12/31/2010 TOTAL GRANT: $522,181 PROJECT: Spectroscopic Imaging of Antioxidant Metabolism in Brain SPONSO: North Carolina State University (National Institute on Aging; NIH) TERM: 08/01/08-08/31/2009 TOTAL GRANT: $31,030

Health Sciences P u b l i c at io n s Indra Balachandran Balachandran I, Walker J, Taylor J, Cheng, M, Wheeler, ME. The impact of New York State’s new licensure regulations for laboratory professionals on staffing of clinical laboratories.

Journal of Allied Health. 2009. (In Press).

Hassan El-Fawal El-Fawal, HAN. Neurotoxicity: Common themes and biomarkers. Encyclopedia of Environmental Health. Elseviers Publishing: London, UK. 2009.

(In Press).

Lawrence Lansing Fares, RR, Lansing, LS, Gallati, CA, Mousa, SA. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opinion in Pharmacotherapy. 2008;9:377-386.

Davis, PJ. Zhou, M, Davis, F, Lansing, L, Mousa, SA, Lin, HY. Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiology and Behavior. 2009.

A b s t r a c t s / P r e s e n tat io n s Indra Balachandran Balachandran I. Cytology of Small Cell Tumors of Childhood. American Society of Cytopathology Cytoteleconference Series, April 2008-March 2009.

Hassan El-Fawal El-Fawal, HAN. Neurantibodies, oxidative stress and calpain activity in lead neurotoxicity. 25th Annual Neurotxicology Conference.

Rochester, NY, 2008.

McCain, W, Henson, TM, Mozzachio, K, Leach, G, El-Fawal, HAN. Rat serum antibodies indicate oxidative stress and renal toxicity, but not neurotoxicity following subchronic exposure to sodium tungstate. The Toxicologist. 2009;29: 75.

El-Fawal, HAN, Gillespie, P, Kang, GS, Chen, LC. Nickel (NI) nanoparticle (NP) inhalation induce serum neuroautoantibodies in C57 mice: Time response to 5 month exposure. The Toxicologist. 2009;29:201.

Gr ants Indra Balachandran PROJECT: Acquisition of a ThinPrep® 2000 Processor for education, training and research for the Cytotechnology Program in Albany College of Pharmacy and Health Sciences SPONSOR: The Community Foundation for the Capitol Region, Albany, NY TERM: 09/08/2008 TOTAL AWARD: $10,000

Student Scholarly Accomplishments Supervised by Faculty The following Cytotechnology students worked with Indra Balachandran and Joe Walker presented at the American Society of Cytotechnology Student Interesting Case Presentation at the ASCT Annual Conference April 16-19, 2009, St. Petersburg, FL. Naima Kim: FNA of lymph node with metastatic small cell carcinoma Joshua Koppenhaffer: FNA of thyroid with metastatic small cell carcinoma Melissa Paoni: Cryptococcus in an FNA of a neck mass Helina Patel: FNA of islet cell tumor Zachary Sletten: Fine Needle Aspiration Cytology (FNA) of Malignant Fibrous Histiocytoma Allison Yelton: Rhabdomyosarcoma: A Case Study with cervical lymph node metastasis

A l b a n y C o l l e g e o f P h a r m ac y a n d H e a lt h S c i e n c e s James J. Gozzo, Ph.D. President

Mehdi Boroujerdi, Pharm.D., Ph.D. Dean

Board of Trustees officers

term trustees

Alfred J. Collins Jr. ’53 Chair

James E. Bollinger ’58 Robert S. Busch Herbert Chorbajian Kandyce J. Daley ’74 Richard H. Daffner ’63 Melvin Friedland ’58 Geno J. Germano ’83 Zachary I. Hanan ’63 Hugh A. Johnson Jeannette S. Lamb ’57 Joseph M. Lapetina

J. Gordon Dailey ’57 Vice Chair Christopher DelVecchio ’88 Treasurer Bridget-Ann Hart ’80 Secretary

Robert F. McGaugh ’57 Thomas O. Maggs Christopher Mitiguy Fouad Morkos Richard G. Robison ’52 Stephen C. Ainlay trustees emeriti

Michael F. Bette Kenneth M. Nirenberg

c o n s u lta n t to the board

Francis J. DiLascia ’54 office of grants a d m i n i s t r at i o n

Sunita Chowfin Grants Administrator Diane Vincent Grants and Contracts Accounting Manager

Office of Institutional Advancement Vicki A. DiLorenzo Vice President of Institutional Advancement David Zdunczyk Assistant Vice President of Institutional Advancement Michael J. Buckley Major Gifts Officer

Gil Chorbajian Executive Director of Marketing and Communications Deanna Ennello-Butler Director of Advancement Research Bill Jabour Director of Annual Giving and Alumni Relations

www.acphs.edu

Candace Madden Systems Administrator Patrick Rathbun Assistant Director of Marketing and Communications Donna Reichel Assistant Director of Marketing and Communications

Debbie Reutter Coordinator of Institutional Advancement Christina Sanvidge Coordinator of Donor Relations Patty Tompkins Events Manager

n o n - p r o fit o r g us p o s tag e

paid

albany ny p er mit n o . 3 4 9 106 New Scotl and Avenue, Al bany NY 12 2 0 8